Moderna seeks US approval of second COVID booster

booster vaccine
Credit: Pixabay/CC0 Public Domain

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's COVID-19 vaccine for all adults.

The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 in adults 18 years of age and older who have received an initial booster" of any approved COVID jab, Moderna said on Twitter.

The request comes days after Pfizer-BioNTech, makers of the other COVID mRNA vaccine, also requested emergency approval for a second booster shot, but their request was limited to adults aged 65 and older.

Moderna said in a separate statement that its request had a broader scope so the Centers for Disease Control and Prevention (CDC) and could have "flexibility" in determining appropriate use of the second booster, such as for seniors or immunocompromised people.

The request was based partly on recent data from the United States and Israel about how well the Moderna shot protected against the Omicron variant of the coronavirus.

Pfizer also based its request off two Israeli studies, which it said in a press statement show "an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and ."

The first Israeli study showed that "rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received an additional booster dose," compared to those who only had one.

The analysis was limited to people age 60 and older who received their second booster four months after their first.

The second study—an analysis of Israeli health care workers 18 and up—showed that antibody levels in those who received a second booster were significantly higher than those who did not.

Since the initial regimen of both the Pfizer-BioNTech and Moderna vaccines is two doses, a second would be most individuals' fourth jab.

Recent studies have offered evidence that while a third mRNA vaccine dose raises antibody levels above those of the initial regimen, a fourth dose only returns individuals' levels to that same highly-elevated level.

© 2022 AFP

Citation: Moderna seeks US approval of second COVID booster (2022, March 18) retrieved 15 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Pfizer asks US to allow 4th COVID vaccine dose for seniors


Feedback to editors